vs
ANGIODYNAMICS INC（ANGO）与Anika Therapeutics, Inc.（ANIK）财务数据对比。点击上方公司名可切换其他公司
ANGIODYNAMICS INC的季度营收约是Anika Therapeutics, Inc.的2.6倍（$79.4M vs $30.6M）。Anika Therapeutics, Inc.净利率更高（1.0% vs -8.0%，领先8.9%）。ANGIODYNAMICS INC同比增速更快（9.0% vs 0.0%）。ANGIODYNAMICS INC自由现金流更多（$4.2M vs $4.0M）。过去两年ANGIODYNAMICS INC的营收复合增速更高（2.8% vs 2.7%）
AngioDynamics是一家全球医疗技术企业，专注于研发、生产及销售微创医疗设备，核心产品覆盖血管通路、外科消融、肿瘤治疗等领域，面向北美、欧洲、亚太地区的医院、门诊手术中心及各类医疗机构提供服务。
ANGO vs ANIK — 直观对比
营收规模更大
ANGO
是对方的2.6倍
$30.6M
营收增速更快
ANGO
高出9.0%
0.0%
净利率更高
ANIK
高出8.9%
-8.0%
自由现金流更多
ANGO
多$250.0K
$4.0M
两年增速更快
ANGO
近两年复合增速
2.7%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $79.4M | $30.6M |
| 净利润 | $-6.3M | $292.0K |
| 毛利率 | 56.4% | 62.6% |
| 营业利润率 | -7.7% | 2.1% |
| 净利率 | -8.0% | 1.0% |
| 营收同比 | 9.0% | 0.0% |
| 净利润同比 | 40.9% | 101.3% |
| 每股收益（稀释后） | $-0.15 | $0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANGOANIK
| Q4 25 | $79.4M | $30.6M | ||
| Q3 25 | $75.7M | $27.8M | ||
| Q2 25 | $80.2M | $28.2M | ||
| Q1 25 | $72.0M | $26.2M | ||
| Q4 24 | $72.8M | $30.6M | ||
| Q3 24 | $67.5M | $29.6M | ||
| Q2 24 | $71.0M | $30.7M | ||
| Q1 24 | $75.2M | $29.0M |
净利润ANGOANIK
| Q4 25 | $-6.3M | $292.0K | ||
| Q3 25 | $-10.9M | $-2.3M | ||
| Q2 25 | $-6.0M | $-4.0M | ||
| Q1 25 | $-4.4M | $-4.9M | ||
| Q4 24 | $-10.7M | $-21.9M | ||
| Q3 24 | $-12.8M | $-29.9M | ||
| Q2 24 | $-13.4M | $-88.0K | ||
| Q1 24 | $-187.7M | $-4.5M |
毛利率ANGOANIK
| Q4 25 | 56.4% | 62.6% | ||
| Q3 25 | 55.3% | 56.0% | ||
| Q2 25 | 52.7% | 50.9% | ||
| Q1 25 | 54.0% | 56.1% | ||
| Q4 24 | 54.8% | 56.0% | ||
| Q3 24 | 54.4% | 65.7% | ||
| Q2 24 | 54.3% | 66.7% | ||
| Q1 24 | 47.7% | 65.4% |
营业利润率ANGOANIK
| Q4 25 | -7.7% | 2.1% | ||
| Q3 25 | -14.1% | -11.6% | ||
| Q2 25 | -7.2% | -14.8% | ||
| Q1 25 | -13.9% | -16.4% | ||
| Q4 24 | -15.2% | -2.3% | ||
| Q3 24 | -19.4% | -0.3% | ||
| Q2 24 | -20.4% | -5.9% | ||
| Q1 24 | -265.9% | -8.6% |
净利率ANGOANIK
| Q4 25 | -8.0% | 1.0% | ||
| Q3 25 | -14.4% | -8.4% | ||
| Q2 25 | -7.5% | -14.1% | ||
| Q1 25 | -6.1% | -18.6% | ||
| Q4 24 | -14.7% | -71.4% | ||
| Q3 24 | -19.0% | -101.2% | ||
| Q2 24 | -18.9% | -0.3% | ||
| Q1 24 | -249.7% | -15.6% |
每股收益（稀释后）ANGOANIK
| Q4 25 | $-0.15 | $0.02 | ||
| Q3 25 | $-0.26 | $-0.16 | ||
| Q2 25 | $-0.15 | $-0.28 | ||
| Q1 25 | $-0.11 | $-0.34 | ||
| Q4 24 | $-0.26 | $-1.49 | ||
| Q3 24 | $-0.31 | $-2.03 | ||
| Q2 24 | $-0.35 | $0.00 | ||
| Q1 24 | $-4.67 | $-0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.6M | $81.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $176.3M | $143.5M |
| 总资产 | $269.7M | $190.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANGOANIK
| Q4 25 | $41.6M | $81.2M | ||
| Q3 25 | $38.8M | $80.2M | ||
| Q2 25 | $55.9M | $77.1M | ||
| Q1 25 | $44.8M | $75.4M | ||
| Q4 24 | $54.1M | $79.2M | ||
| Q3 24 | $55.0M | $90.7M | ||
| Q2 24 | $76.1M | $96.6M | ||
| Q1 24 | $78.5M | $100.7M |
总债务ANGOANIK
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | — | — |
股东权益ANGOANIK
| Q4 25 | $176.3M | $143.5M | ||
| Q3 25 | $178.9M | $146.8M | ||
| Q2 25 | $183.0M | $147.7M | ||
| Q1 25 | $185.9M | $148.4M | ||
| Q4 24 | $186.8M | $154.0M | ||
| Q3 24 | $196.6M | $179.9M | ||
| Q2 24 | $205.6M | $210.3M | ||
| Q1 24 | $218.7M | $208.5M |
总资产ANGOANIK
| Q4 25 | $269.7M | $190.3M | ||
| Q3 25 | $265.6M | $189.4M | ||
| Q2 25 | $280.1M | $187.7M | ||
| Q1 25 | $285.4M | $190.6M | ||
| Q4 24 | $291.6M | $202.7M | ||
| Q3 24 | $293.6M | $231.4M | ||
| Q2 24 | $317.7M | $262.7M | ||
| Q1 24 | $324.8M | $263.7M |
负债/权益比ANGOANIK
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.7M | $4.6M |
| 自由现金流经营现金流 - 资本支出 | $4.2M | $4.0M |
| 自由现金流率自由现金流/营收 | 5.3% | 13.0% |
| 资本支出强度资本支出/营收 | 0.5% | 2.1% |
| 现金转化率经营现金流/净利润 | — | 15.88× |
| 过去12个月自由现金流最近4个季度 | $-9.3M | $4.4M |
8季度趋势，按日历期对齐
经营现金流ANGOANIK
| Q4 25 | $4.7M | $4.6M | ||
| Q3 25 | $-15.9M | $6.9M | ||
| Q2 25 | $18.8M | $-189.0K | ||
| Q1 25 | $-13.2M | $-130.0K | ||
| Q4 24 | $2.5M | $1.6M | ||
| Q3 24 | $-18.3M | $5.0M | ||
| Q2 24 | $5.0M | $-1.1M | ||
| Q1 24 | $-12.5M | $-126.0K |
自由现金流ANGOANIK
| Q4 25 | $4.2M | $4.0M | ||
| Q3 25 | $-16.6M | $5.0M | ||
| Q2 25 | $18.0M | $-1.7M | ||
| Q1 25 | $-15.0M | $-3.0M | ||
| Q4 24 | $1.7M | $275.0K | ||
| Q3 24 | $-19.3M | $3.8M | ||
| Q2 24 | $4.4M | $-4.5M | ||
| Q1 24 | $-13.1M | $-1.9M |
自由现金流率ANGOANIK
| Q4 25 | 5.3% | 13.0% | ||
| Q3 25 | -22.0% | 17.9% | ||
| Q2 25 | 22.5% | -5.9% | ||
| Q1 25 | -20.8% | -11.3% | ||
| Q4 24 | 2.3% | 0.9% | ||
| Q3 24 | -28.7% | 12.9% | ||
| Q2 24 | 6.2% | -14.6% | ||
| Q1 24 | -17.5% | -6.7% |
资本支出强度ANGOANIK
| Q4 25 | 0.5% | 2.1% | ||
| Q3 25 | 1.0% | 6.8% | ||
| Q2 25 | 1.0% | 5.2% | ||
| Q1 25 | 2.5% | 10.8% | ||
| Q4 24 | 1.1% | 4.3% | ||
| Q3 24 | 1.6% | 4.1% | ||
| Q2 24 | 0.8% | 11.1% | ||
| Q1 24 | 0.8% | 6.2% |
现金转化率ANGOANIK
| Q4 25 | — | 15.88× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANGO
| Med Device | $37.2M | 47% |
| Med Tech | $30.4M | 38% |
| Other | $11.8M | 15% |
ANIK
| OEM Channel | $17.3M | 57% |
| Commercial Channel | $13.3M | 43% |
